This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo
News

Draft NICE guidance recommends PLASMA system for transurethral resection of the prostate

National Institute for Health and Care Excellence (NICE) has published draft guidelines which recommend that the PLASMA system (previously TURis) for prostate resection and haemostasis should be considered as an option for people with symptomatic benign prostatic hyperplasia when surgical intervention is indicated.

In making the decision, NICE considered 11 articles. All studies reported equivalent clinical effectiveness for resection of the prostate for PLASMA compared with monopolar transurethral resection of the prostate (mTURP).

No cases of transurethral resection syndrome were seen with PLASMA. In the three studies where it was reported, fewer people needed a blood transfusion in the PLASMA group compared with mTURP. The system reduced the length of hospital stay in two studies.

Cost modelling estimates that the PLASMA system produces savings of £459 per procedure compared with mTURP for hospitals that already use an Olympus platform and £343 for those that do not. Furthermore, PLASMA is associated with reduced readmissions compared with mTURP, leading to savings of £534 and £418 for hospitals that already use an Olympus platform and those that do not, respectively.

Clinical outcomes are as good as for conventional mTURP, but with less chance of serious complications.

The evidence supports the case for adopting the PLASMA system for bipolar transurethral saline resection and haemostasis of the prostate in the NHS, NICE concluded.

The guidance is now open to for public comment. The deadline for receipt of comments is 5 pm, 9 October 2020.


References


YOU MAY ALSO LIKE